Kyoko Inagaki

Current Diagnosis and Management of Primary Chylomicronemia

H. Daida, K. Matsuki, S. Yokoyama, 2021, Journal of atherosclerosis and thrombosis.

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data

A. Tsubota, K. Iwakiri, H. Sugihara, 2021, Therapeutic advances in endocrinology and metabolism.

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus

A. Tsubota, K. Iwakiri, H. Sugihara, 2022, Hepatology communications.

Identification of serum metabolome signatures associated with retinal and renal complications of type 2 diabetes

Y. Kamatani, Y. Okada, Y. Furukawa, 2023, Communications Medicine.

[Internal medicine and neurological diseases: progress in diagnosis and treatment. Topics: II neurological diseases related to diabetes mellitus; 2. Cerebral infarction, coma, hypoglycemia].

Mototsugu Nagao, S. Oikawa, Kyoko Inagaki, 2012, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease

A. Tsubota, K. Iwakiri, H. Sugihara, 2021, Scientific Reports.

Diagnosis and Management of Sitosterolemia 2021

S. Yamashita, K. Matsuki, K. Tsukamoto, 2021, Journal of atherosclerosis and thrombosis.

Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals

S. Yamashita, T. Okamura, M. Kuzuya, 2020, Journal of atherosclerosis and thrombosis.

Clinical Characteristics of Homozygous Familial Hypercholesterolemia in Japan

S. Yamashita, K. Matsuki, T. Miida, 2023, JACC. Asia.